Legal status (US): Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta WR, manufactured by Theratechnologies, specifically to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy
NICE guidance (NG28) recommends GLP-1 receptor agonists in type 2 diabetes only for specific patients, typically when other treatments have proven insufficient and when certain BMI thresholds are met
It is a solid option for cost-conscious patients who are comfortable with a streamlined, medication-focused approach
We thus injected AAV-VGAT-eNpHR-EYFP into the APC region and implanted optic fibers bilaterally over the MD, enabling a circuit-specific inhibition in freely moving mice
Kobayashi, T., Shiba, T., Kinoshita, A., Matsumoto, T
GLP-1 (GLP-1R) DPP-4 T2DM